Agreements reached under this partnership
Business Alliances- 1
Through DDAIF, centered on its equation-driven AI platform “KIBIT,” FRONTEO will comprehensively search for novel indications that have not been reported in existing academic literature for assets specified by clients, while presenting hypotheses regarding the mechanisms through which those assets may be effective in treating the relevant diseases.
- 2
CMIC’s Consulting and Navigation Unit will investigate and add information on the therapeutic value of the indication candidates presented by FRONTEO, taking into account unmet medical needs in clinical practice and assessing their market potential and development feasibility. The unit will also draw on medical data, market and competitive intelligence, insights into the feasibility of clinical development, and expertise from specialists in disease areas developed through experience in the pharmaceutical and healthcare sectors.
- 3
Based on the information provided by both companies, pharmaceutical companies will compare, select and prioritize indications and determine the direction of their indication strategies.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
| Item | Details |
|---|---|
| Name of alliance partner | CMIC HOLDINGS Co., Ltd. |
| Alliance partner's business activities | Evaluation and consulting services drawing on medical data, market and competitive intelligence, insights into the feasibility of clinical development, and expertise from specialists in disease areas, developed through experience in the pharmaceutical and healthcare sectors. Support services related to the development, regulatory affairs, manufacturing and sale of pharmaceuticals and medical devices. |
| Alliance partner's location | Minato-ku, Tokyo |
| Type of alliance | Business Alliances |
| Details of the alliance | Through DDAIF, centered on its equation-driven AI platform “KIBIT,” FRONTEO will comprehensively search for novel indications that have not been reported in existing academic literature for assets specified by clients, while presenting hypotheses regarding the mechanisms through which those assets may be effective in treating the relevant diseases., CMIC’s Consulting and Navigation Unit will investigate and add information on the therapeutic value of the indication candidates presented by FRONTEO, taking into account unmet medical needs in clinical practice and assessing their market potential and development feasibility. The unit will also draw on medical data, market and competitive intelligence, insights into the feasibility of clinical development, and expertise from specialists in disease areas developed through experience in the pharmaceutical and healthcare sectors., Based on the information provided by both companies, pharmaceutical companies will compare, select and prioritize indications and determine the direction of their indication strategies. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Pharmaceutical companies sometimes decide not to proceed with development even for scientifically promising indications because of business considerations. The challenge in decision-making was that scientific discovery findings had not been sufficiently integrated with business and development assessments.